Withdrawal of the marketing authorisation application
On 14 November 2008, Novagali Pharma S.A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Vekacia, for the treatment of vernal keratoconjunctivitis. Vekacia was designated as an orphan medicinal product on 6 April 2006.
|International non-proprietary name (INN) or common name||
|Date of withdrawal||
|Company making the application|
Withdrawal assessment report for Vekacia (PDF/134.17 KB)Adopted
First published: 26/02/2009
Last updated: 26/02/2009
Novagali Pharma S.A. withdraws its marketing authorisation application for Vekacia (ciclosporin) (PDF/23.81 KB)
First published: 17/11/2008
Last updated: 17/11/2008
Withdrawal letter : Vekacia (PDF/19.14 KB)
First published: 14/11/2008
Last updated: 14/11/2008
Questions and answers on the withdrawal of the marketing application for Vekacia (PDF/39.72 KB)
First published: 02/12/2008
Last updated: 02/12/2008
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').